消息面上,据康龙化成官微消息,7月7日,康龙化成宣布,中国首台应用于新药研发的低能耗加速器质谱(Accelerator Mass Spectrometry,AMS)在宁波完成安装调试,助力公司进一步提升放射性同位素高灵敏度、微量示踪药物代谢和生物分析服务能力。目前,公司已经在中、英、美三地战略布局四台AMS,形成全球协同的研发服务网络。此次最新一代的高通量AMS落户宁波,标志着公司“放射性同位素药物标记合成-临床研究-分析检测”一体化研发服务平台的全面升级,助力公司技术实力持续领跑全球,为客户提供更高效、更精准、更灵活的解决方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.